Abstract 235P
Background
Radiation therapy (RT) is not a standard treatment for ovarian cancer (OC). However, it can be used as an adjunctive therapy to control the local recurrent disease. We aimed to investigate whether OC patients could benefit from RT.
Methods
From 2004 to 2013, the incidence, survival, treatment, and end results data from the SEER were analyzed for cases diagnosed with OC. We examined cause-specific survival (CSS) and overall survival (OS) with 95% confidence intervals (CIs) to estimate the effect of RT from multivariate Cox regression analysis. Performed propensity score matching (PSM) method was used for OC patients who received radiotherapy versus those who did not.
Results
A total of 11140 cases were enrolled for analysis. The aggregated HR of univariate survival analysis suggested that radiotherapy had unfavorable effects on overall survival (HR 1.315, 95% CI 0.994–1.739, P = 0.055) and cancer-specific survival (HR 1.732, 95% CI 1.285–2.334, P < 0.001), but there is no significant difference in multivariate analysis (OS HR 1.315, 95% CI 0.994–1.739, P = 0.055; CSS HR 1.222, 95% CI 0.905–1.651, P = 0.191). After PSM by 1:4, 655 patients were included. Both of the effect of radiotherapy in overall survival (HR 1.341, 95% CI 0.977–1.84, P = 0.070) and cancer-specific survival (HR 1.309, 95% CI 0.931–1.838, P = 0.121) were not significant ever in univariate analysis. Multivariate analysis also found the same results (OS HR 1.232, 95% CI 0.894–1.699, P = 0.202; CSS HR 1.187, 95% CI 0.841–1.674, P = 0.330). Radiotherapy seems to have a reverse effect in regionally spread patients in stage II patients (before PMS HR 3.154, 95% CI 1.709-5.821, p < 0.01; after PMS HR = 3.543, 95% CI 1.603-7.834, p < 0.01) and non-epithelial OC patients (before PMS HR 1.748, 95% CI 1.219-2.507, p = 0.002; after PMS HR = 1.5422, 95% CI 1.021-2.329, p = 0.04).
Conclusions
In OC patients, RT does not have a proven benefit on CSS and OS overall, and it is especially not suitable for early-stage patients and non-epithelial OC patients. However, further confirmation is needed from well-designed and large-scale RCTs in the future to identify its effect in certain types of epithelial OC patients after the developed techniques.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract